U.S. markets closed

Nanobiotix S.A. (NBTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.45+0.20 (+3.20%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close6.25
Bid3.18 x 800
Ask6.61 x 800
Day's Range6.28 - 6.45
52 Week Range1.75 - 11.00
Avg. Volume18,918
Market Cap328.897M
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-1.82
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.06
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NBTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Nanobiotix S.A.
    Daily – Vickers Top Buyers & Sellers for 12/22/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Voting Rights and Shares Capital of the Company

    In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights,exercisable

  • GlobeNewswire

    Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

    PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder of Nanobiotix and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on


    Baillie Gifford Bolsters Stake in Nanobiotix SA

    Baillie Gifford (Trades, Portfolio), the renowned investment management firm, has recently increased its investment in Nanobiotix SA, a company at the forefront of nanotechnology in cancer treatment. This transaction was executed at a trade price of $5.81 per share, reflecting a 48.18% change in the firm's holdings and a 6.21% ownership in Nanobiotix SA. Despite the significant addition, the trade had a negligible impact on Baillie Gifford (Trades, Portfolio)'s portfolio, with the position accounting for just 0.02% of its total investments.